Workflow
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
ACETAdicet Bio(ACET) Investor Place·2024-06-10 23:22

Core Viewpoint - Biotech stocks under 10presentpotentialinvestmentopportunitiesduetoupcomingcatalystsandashiftinfocusbacktothesectorpost−pandemic[1]Group1:ActiniumPharmaceuticals(ATNM)−ActiniumPharmaceuticalsisaclinical−stagebiopharmacompanyfocusedontargetedradiotherapies,withitsIomab−Bcandidateinlate−stage(Phasethree)clinicaltrials[2]−PositiveresultsfrompivotalphasethreeSIERRAtrialsandplannedregulatoryfilingssuggestapotentialsurgeinATNMstock[2]−Thecompanyhasacashbufferof10 present potential investment opportunities due to upcoming catalysts and a shift in focus back to the sector post-pandemic [1] Group 1: Actinium Pharmaceuticals (ATNM) - Actinium Pharmaceuticals is a clinical-stage biopharma company focused on targeted radiotherapies, with its Iomab-B candidate in late-stage (Phase three) clinical trials [2] - Positive results from pivotal phase three SIERRA trials and planned regulatory filings suggest a potential surge in ATNM stock [2] - The company has a cash buffer of 84 million, expected to fund operations into the second half of 2026, supporting pipeline development [3] Group 2: Adicet Bio (ACET) - Adicet Bio has experienced a 75% decline in stock price over the last 12 months, but received fast track designation from the FDA for its ADI-001 candidate, which could expedite drug review [5] - The company closed a 98 million public follow-on offering in March, contributing to equity dilution concerns, but the fast-track designation provides flexibility for R&D financing [5] - Adicet is building a pipeline with clinical updates expected in the second half of 2024 and 2025, with a cash runway extending into the second half of 2026 [6] Group 3: Entera Bio (ENTX) - Entera Bio's stock has corrected from highs of 3.35 to $2, presenting an accumulation opportunity for potential future rallies [7] - The company focuses on orally delivered peptide and protein therapeutics, with its most advanced candidate, EB613, targeting high-risk post-menopausal osteoporosis [7] - Entera Bio has a cash runway through the first half of 2025, alleviating immediate equity dilution concerns, and multiple programs are expected to enter clinical stages in 2025 [8]